Breaking News
July 18, 2018 - Hunger hormones could be key to new treatments for drug, alcohol addiction
July 18, 2018 - Nitrate-cured meats may contribute to mania, study finds
July 18, 2018 - Why men may recover more quickly from influenza infections than women
July 18, 2018 - KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
July 18, 2018 - Self-control and obesity: Gender matters in children
July 18, 2018 - Bioengineers, diabetes researchers convene to discuss future concepts for precision medicine
July 18, 2018 - Practicing yoga benefits pregnant women, study suggests
July 18, 2018 - FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
July 18, 2018 - Deep data dive helps predict cerebral palsy
July 18, 2018 - Stricter firearm legislation associated with reduced murder and suicide rates
July 18, 2018 - Physical and sexual abuse in childhood associated with endometriosis risk
July 18, 2018 - Omega 3 supplements do not reduce risk of heart disease, stroke or death
July 18, 2018 - GSA’s new publication provides support for safe use of OTC analgesics by older adults
July 18, 2018 - Researchers receive grant from U.S. Department of Education to study children with HFASD
July 18, 2018 - Early childhood adversity increases sensitivity of the body’s immune response to cocaine
July 18, 2018 - Parental incarceration affects health behaviors of children in adulthood
July 18, 2018 - Researchers find that yellow fever and Asian tiger mosquitoes can carry new virus
July 18, 2018 - Two Regimens Fail to Stop Declines in β-Cell Function
July 18, 2018 - Researchers apply computing power to track the spread of cancer
July 18, 2018 - Olfactory receptors play pathophysiological role in all organs than merely smell perception
July 18, 2018 - Fish consumption associated with lower risk of early death
July 18, 2018 - MR Solutions’ 7T MRI imaging system installed at University of Hawaii
July 18, 2018 - Humorous ads screened around World Cup game achieve higher biometric response than sporty ads
July 18, 2018 - New study demonstrates little effect of hormone therapy on artery thickness
July 18, 2018 - A 3-Pronged Plan to Cut Type 2 Diabetes Risk
July 18, 2018 - New clues to sepsis may speed diagnosis
July 18, 2018 - Stars of Stanford Medicine: Improving cardiovascular health in Africa and beyond
July 18, 2018 - Heart attack risk continues to increase among pregnant women, study finds
July 18, 2018 - Few tips to help avoid sunburns in summer
July 18, 2018 - High-fat diet and systemic inflammation contribute to progression of prostate cancer
July 18, 2018 - Researchers develop 3D map of gene interactions that play key role in heart disease
July 18, 2018 - Conservative management of lung subsolid nodules reduces overtreatment and unnecessary surgery
July 18, 2018 - Report warns of dog illness that can spread to owners
July 18, 2018 - A winning essayist’s tips for keeping track of scientific facts
July 18, 2018 - Researchers seek to understand role of APOE mutation in Alzheimer’s disease
July 18, 2018 - Animal studies reveal brain changes responsible for appetite effects of cannabis
July 18, 2018 - New ZEISS ZEN Intellesis machine allows segmentation of correlative microscopy
July 18, 2018 - Study findings highlight importance of early detection of SMA through newborn screening
July 18, 2018 - Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of Pixuvri (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
July 18, 2018 - Diabetes researchers find switch for fatty liver disease
July 18, 2018 - The future of the microbiome: A conversation
July 18, 2018 - States attacking ACA would hurt most if shield on preexisting conditions were axed
July 18, 2018 - Novel delivery system for bacteriophages could offer new way to battle lung infections
July 18, 2018 - PTSD may increase risk of stroke, heart attack in World Trade Center response crews
July 18, 2018 - Finding the right protective eyewear for young athletes
July 18, 2018 - Routine screening, treatment could help stem nationwide opioid epidemic
July 17, 2018 - AI and radar technologies could help diabetics manage their disease
July 17, 2018 - New Stanford algorithm could improve diagnosis of many rare genetic diseases
July 17, 2018 - Burdensome symptoms of eczema can lead to impaired quality of life, shows study
July 17, 2018 - Sartorius Stedim Biotech and Penn State partner to advance teaching, research in biotechnology
July 17, 2018 - Researchers map family trees of cancer cells to understand how AML responds to new drug
July 17, 2018 - Mortality from heart failure remains higher in women than men
July 17, 2018 - Can-Fite BioPharma receives Australian and Chinese patents for new drug to treat erectile dysfunction
July 17, 2018 - AAP: Lawnmowers Pose Serious Injury Risk to Children
July 17, 2018 - Fewer U.S. kids are getting cavities
July 17, 2018 - Differences in brain’s reward circuit may explain social deficits in autism
July 17, 2018 - YCC researchers suggest promising treatment for two rare inherited cancer syndromes
July 17, 2018 - FAU and partners receive NIH research grant to shed light on sleep loss and metabolic disorders
July 17, 2018 - Advanced MRI technique predicts risk of disease progression in MS
July 17, 2018 - Health Tip: Microwave Safely – Drugs.com MedNews
July 17, 2018 - New target for treating heart failure identified
July 17, 2018 - Biodesign fellows simplify heart rhythm monitoring
July 17, 2018 - Study reveals new risk genes for allergic rhinitis
July 17, 2018 - Community college education can increase physician diversity and access to primary care
July 17, 2018 - Inflection Biosciences’ dual mechanism inhibitor shows promise as treatment for CLL
July 17, 2018 - Researchers uncover how cells invite corrupted proteins inside
July 17, 2018 - Large international study finds new risk genes for hay fever
July 17, 2018 - Studies show HORIBA’s new hematology analyzer improves POCT and care of oncology patients
July 17, 2018 - New website aims to make yoga safer for everyone
July 17, 2018 - Long-term survival worse for black survivors of in-hospital cardiac arrest
July 17, 2018 - Stanford data analyst’s childhood inspires his research: A Q&A
July 17, 2018 - Preventability of hospital readmissions changes over time, study reveals
July 17, 2018 - Nursing notes can help predict if ICU patients will survive
July 17, 2018 - Most older adults with probable dementia found to be either undiagnosed or unaware of it
July 17, 2018 - Vallum receives FDA clearance to market PEEK spinal interbody fusion device
July 17, 2018 - Okayama University research could improve prognosis of diabetic kidney disease
July 17, 2018 - Researchers develop machine learning method to predict unknown gene functions of microbes
July 17, 2018 - Homogenous BTK occupancy assay used in tirabrutinib clinical studies
July 17, 2018 - Study identifies new genes linked to heart function and development
July 17, 2018 - NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology
Clinical trial targets metastatic colorectal cancer with new combination therapy

Clinical trial targets metastatic colorectal cancer with new combination therapy

image_pdfDownload PDFimage_print

Rutgers Cancer Institute of New Jersey is offering a clinical trial targeting an advanced form of colorectal cancer with a combination vaccine/immunotherapy drug treatment.

The standard way of treating colorectal cancer that has spread to the liver or has recurred is with a combination of chemotherapy and removal of the cancer through surgery. This however, is not always effective as the majority of patients suffer a recurrence of their cancer following standard treatment. This emphasizes the need for new therapies that can prevent the cancer from coming back. Researchers at Rutgers Cancer Institute are exploring the combination of a new anti-cancer vaccine with an immunotherapy drug approved for use in other forms of cancer to determine if the combined treatment can prompt a patient’s natural defenses (the immune system) to attack their cancer and improve their survival. Investigators also will determine if the vaccine/immunotherapy combination works better than if just the immunotherapy drug was given with chemotherapy and surgery.

The investigational vaccine therapy is a newer version of a poxvirus-based cancer treatment formerly called PANVAC. PANVAC has been tested in more than 15 clinical trials and found to be safe. One of these trials was completed at Rutgers Cancer Institute in patients with pancreatic cancer. Given by injection, PANVAC helps stimulate the immune system against infection to recognize and destroy tumor cells that produce specific proteins. PANVAC has recently undergone some changes to improve it, and the newer version is now called CV301. Nivolumab is a different drug that is approved the U.S. Food and Drug Administration to treat other forms of cancer including melanoma, lung cancer and Hodgkin lymphoma, but not pancreatic cancer. It is considered investigational in this clinical trial. Nivolumab also stimulates the immune system.

Darren R. Carpizo, MD, PhD, director of the Liver Cancer and Bile Duct Cancer Program at Rutgers Cancer Institute is the lead investigator on the clinical trial. “In approximately 80 percent of colorectal cancer patients whose disease has spread to the liver, the cancer comes back after surgery. With that, clinical trials aimed at testing new therapies to prevent recurrence are desperately needed. Immunotherapy drugs known as ‘checkpoint inhibitors’ have already made a significant impact in the treatment of several cancers, but only a minority of patients respond to them. Combining these drugs with other forms of immunotherapy such as vaccines (as designed in this trial) has the potential to increase the number of patients who benefit from them. CV301 is an exciting choice as the vaccine to partner with nivolumab, as its former version (PANVAC) has shown activity previously in this patient population,” notes Dr. Carpizo, who is also an associate professor of surgery at Rutgers Robert Wood Johnson Medical School.

Patients aged 18 and older who are diagnosed with colorectal cancer that has spread to the liver and can be removed by surgery are eligible to take part in the clinical trial. Other criteria also must be met. Prior to being accepted into the clinical trial, participants are required to undergo a number of tests including bloodwork and a physical exam.

Eligible participants will be assigned randomly (by chance) into two groups. One group will receive nivolumab and the standard chemotherapy given for colorectal cancer that has spread to the liver in addition to surgery. The chemotherapy will be given through a vein. The second group will receive chemotherapy treatment, surgery, nivolumab and the CV301 vaccine treatment. Those receiving the vaccine treatment will receive it through injection into a fatty part of the skin at multiple intervals prior to and after surgery. Once treatment is completed, participants will be followed by their health care team and undergo a physical exam, bloodwork and other testing on a regular basis over a five-year period.

The phase II clinical trial will be conducted at Rutgers Cancer Institute of New Jersey and six other centers across the country. It is being supported in part by Bavarian Nordic A/S and Bristol-Myers Squibb and is being managed by Hoosier Cancer Research Network.

Posted in: Drug Trial News | Medical Condition News

Tags: Bile, Bile Duct Cancer, Bladder, Cancer, Cancer Treatment, Chemotherapy, Clinical Trial, Colorectal, Colorectal Cancer, Drugs, Education, Health Care, Hodgkin Lymphoma, Hospital, Immune System, Immunotherapy, Liver, Liver Cancer, Lung Cancer, Lymphoma, Medical School, Melanoma, Pancreatic Cancer, Research, Skin, Surgery, therapeutics, Tumor, Vaccine

Tagged with:

About author

Related Articles